Christopher L Amling
Affiliation: Oregon Health and Science University
- Deciding whom to biopsyChristopher L Amling
Division of Urology, Oregon Health and Science University, Portland, OR 97239, USA
Urol Oncol 28:542-5. 2010..Catalona) and the other arguing for the routine use of established risk nomograms (Dr. Klein)...
- Are repeat prostate biopsies safe? A cohort analysis from the SEARCH databaseRyan P Kopp
Division of Urology, University of California, San Diego, San Diego, California 92103 8897, USA
J Urol 187:2056-60. 2012..Therefore, we investigated whether there is an association between the number of prior biopsy sessions and biochemical recurrence after radical prostatectomy...
- Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital databaseKathleen F McGinley
Division of Urology, Department of Surgery, Duke University, Durham, North Carolina, USA
Int J Urol 23:241-6. 2016..To evaluate performance of pelvic lymph node dissection during radical prostatectomy within an equal access care setting over a period of time, and stratified by prostate cancer risk group and surgical technique...
- Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) databaseEmma H Allott
Division of Urology, Department of Surgery, Duke University School of Medicine, NC, USA Cancer Prevention, Detection and Control Program, Duke Cancer Institute, NC, USA Division of Urology, Veterans Affairs Medical Center Durham, NC, USA
BJU Int 114:661-6. 2014..To investigate the effect of statin use after radical prostatectomy (RP) on biochemical recurrence (BCR) in patients with prostate cancer who never received statins before RP...
- Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH databaseChristopher J Kane
Division of Urology, Department of Surgery, University of California San Diego, San Diego, CA 92103 8897, USA
Urology 76:695-700. 2010..We sought to evaluate outcomes after radical prostatectomy among men with low-risk prostate cancer who would be candidates for active surveillance...
- Prostate cancer screening: what we have learned from the PLCO and ERSPC trialsJeffrey La Rochelle
Department of Surgery, Division of Urology, Oregon Health and Sciences University, 3303 SW Bond Avenue, Mail Code CH10U, Portland, OR, 97239, USA
Curr Urol Rep 11:198-201. 2010..70-0.80). Based on these studies, it is reasonable to conclude that there is a survival benefit for screening, but it may not extend to older men (>75 years) who have undergone prior screening...
- Prostate-specific antigen and detection of prostate cancer: What have we learned and what should we recommend for screening?Christopher L Amling
Division of Urology, FOT 1105, University of Alabama at Birmingham, 1530 Third Avenue South, Birmingham, AL 35294, USA
Curr Treat Options Oncol 7:337-45. 2006..It is hoped that ongoing prospective screening trials will determine the value of PSA screening. However, until these results are available the controversy will continue, and men will continue to be screened...
- Role of lymphadenectomy for prostate cancer: indications and controversiesJeffrey C La Rochelle
Division of Urology, Oregon Health and Science University, 3303 Southwest Bond Avenue, CH10U, Portland, OR 97239, USA
Urol Clin North Am 38:387-95, v. 2011..The improved staging afforded by a more extended dissection raises several questions. Addressing these questions is the focus of this review...
- Biochemical recurrence after localized treatmentChristopher L Amling
Division of Urology, University of Alabama, South Birmingham, AL 35294 3411, USA
Urol Clin North Am 33:147-59, v. 2006..Some treatment strategies discussed in this article include salvage radiotherapy after radical prostatectomy, salvage therapy after radiotherapy, and hormonal therapy...
- Timing, incidence and risk factors for venous thromboembolism in patients undergoing radical cystectomy for malignancy: a case for extended duration pharmacological prophylaxisAmanda A Vandlac
Department of Urology, Oregon Health and Science University, Portland, Oregon
J Urol 191:943-7. 2014..Therefore, we evaluated the timing, incidence and risk factors for venous thromboembolism for patients undergoing radical cystectomy for malignancy...
- Living renal donor allograft lithiasis: a review of stone related morbidity in donors and recipientsAndrew M Strang
Division of Urology, University of Alabama at Birmingham, Birmingham, Alabama 35294 3411, USA
J Urol 179:832-6. 2008..We reviewed current acceptance guidelines for donors with stone disease as well as data on stone related outcomes in donors with stone disease and recipients who received a kidney with a stone left in situ...
- Prostate cancer in men using testosterone supplementationFranklin D Gaylis
Division of Urology, University of California at San Diego Medical Center, San Diego, California, USA
J Urol 174:534-8; discussion 538. 2005..To increase awareness of this risk, we report on a series of patients in whom clinically significant prostate cancer developed and was presumed to be related to exogenous testosterone use...